title: Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.
abstract: Intrastriatal administration of 6-hydroxydopamine (6-OHDA) induces partial degeneration of the nigrostriatal pathway, mimicking the pathology of Parkinson's disease (PD). Setting up the partial lesion model can be challenging because a number of experimental settings can be altered. This study compares seven experimental settings in a single study on d-amphetamine-induced rotations, tyrosine hydroxylase (TH)-positive neurites in the striatum, dopamine transporter (DAT)-positive neurites in the striatum, and TH-positive cells in the substantia nigra pars compacta (SNpc) in rats. Moreover, we validate a new algorithm for estimating the number of TH-positive cells. We show that the behavior and immunoreactivity vary greatly depending on the injection settings, and we categorize the lesions as progressive, stable, or regressive based on d-amphetamine-induced rotations. The rotation behavior correlated with the degree of the lesion, analyzed by immunohistochemistry; the largest lesions were in the progressive group, and the smallest lesions were in the regressive group. We establish a new low-dose partial 6-OHDA lesion model in which a total of 6 μg was distributed evenly to three sites in the striatum at a 10° angle. The administration of low-dose 6-OHDA produced stable and reliable rotation behavior and induced partial loss of striatal TH-positive and DAT-positive neurites and TH-positive cells in the SNpc. This model is highly suitable for neurorestoration studies in the search for new therapies for PD, and the new algorithm increases the efficacy for estimating the number of dopamine neurons. This study can be extremely useful for laboratories setting up the partial 6-OHDA model.
authors.affiliation: Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
authors.forename: Anna-Maija
authors.initials: AM
authors.lastname: Penttinen
authors.affiliation: Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
authors.forename: Ilida
authors.initials: I
authors.lastname: Suleymanova
authors.affiliation: Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
authors.forename: Katrina
authors.initials: K
authors.lastname: Albert
authors.affiliation: Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
authors.forename: Jenni
authors.initials: J
authors.lastname: Anttila
authors.affiliation: Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
authors.forename: Merja H
authors.initials: MH
authors.lastname: Voutilainen
authors.affiliation: Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
authors.forename: Mikko
authors.initials: M
authors.lastname: Airavaara
mesh_terms: D018663:Adrenergic Agents / Q000008:administration & dosage* / Q000633:toxicity*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects; D004195:Disease Models, Animal; D059290:Dopaminergic Neurons / Q000187:drug effects; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D008297:Male; D016627:Oxidopamine / Q000008:administration & dosage* / Q000633:toxicity*; D020734:Parkinsonian Disorders; D051381:Rats; D017208:Rats, Wistar
chemical_list: D018663:Adrenergic Agents; D016627:Oxidopamine
keywords: 6-OHDA; AB_2190413; AB_2201528; RGD_5508396; dopamine; dopamine transporter; nlx_153890; partial striatal lesion; striatum; substantia nigra; tyrosine hydroxylase